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ARTICLE
Mitochondrial calcium exchange links metabolism
with the epigenome to control cellular
differentiation
Alyssa A. Lombardi1, Andrew A. Gibb1, Ehtesham Arif1, Devin W. Kolmetzky1, Dhanendra Tomar 1,
Timothy S. Luongo1, Pooja Jadiya 1, Emma K. Murray1, Pawel K. Lorkiewicz 2, György Hajnóczky 3,
Elizabeth Murphy4, Zoltan P. Arany5, Daniel P. Kelly5, Kenneth B. Margulies5, Bradford G. Hill2 &
John W. Elrod 1
Fibroblast to myofibroblast differentiation is crucial for the initial healing response but
excessive myofibroblast activation leads to pathological fibrosis. Therefore, it is imperative to
understand the mechanisms underlying myofibroblast formation. Here we report that mito-
chondrial calcium (mCa2+) signaling is a regulatory mechanism in myofibroblast differ-
entiation and fibrosis. We demonstrate that fibrotic signaling alters gating of the
mitochondrial calcium uniporter (mtCU) in a MICU1-dependent fashion to reduce mCa2+
uptake and induce coordinated changes in metabolism, i.e., increased glycolysis feeding
anabolic pathways and glutaminolysis yielding increased α-ketoglutarate (αKG) bioavail-
ability. mCa2+-dependent metabolic reprogramming leads to the activation of
αKG-dependent histone demethylases, enhancing chromatin accessibility in loci specific to
the myofibroblast gene program, resulting in differentiation. Our results uncover an important
role for the mtCU beyond metabolic regulation and cell death and demonstrate that mCa2+
signaling regulates the epigenome to influence cellular differentiation.
https://doi.org/10.1038/s41467-019-12103-x OPEN
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F ibroblast to myofibroblast differentiation is a universalresponse to injury whereby fibroblasts differentiate from aquiescent structural role into contractile and synthetic
myofibroblasts, which are vital to wound healing1–3. However,
the reparative characteristics of myofibroblasts also contribute to
pathological fibrosis. These cells produce copious extracellular
matrix (ECM) proteins such as periostin, collagen, and fibro-
nectin, and can remodel tissues due to de novo expression of
α-smooth muscle actin (α-SMA)3,4. Differentiation of fibroblasts
into myofibroblasts is initiated and sustained by several agonists
including: Transforming Growth Factor-beta (TGFβ), Angio-
tensin II (AngII), Endothelin 1 (ET1), and mechanical tension,
which initiate distinct, yet interconnected, signaling pathways1,5.
Since acquisition and retention of the myofibroblast state is an
important mediator of pathological fibrosis, it is important to
define the molecular mechanisms that mediate this differentiation
process3,5–7.
Recently it has become appreciated that a sustained elevation in
cytosolic calcium (cCa2+) promotes the conversion of quiescent
fibroblasts into myofibroblasts. Profibrotic mediators TGFβ,
AngII, and ET1 trigger an increase in cCa2+8–10. In addition,
multiple groups have established transient receptor potential
(TRP) channels as contributors to cardiac fibrosis and myofi-
broblast differentiation. TRPV4, TRPM7, and TRPC6 have
all been implicated in myofibroblast differentiation11–13. While
cCa2+ signaling appears to be necessary for both TGFβ-
dependent and TGFβ-independent signaling pathways, other
cellular Ca2+ domains, such as mitochondrial calcium (mCa2+),
have not been explored. Elevations in cCa2+ are rapidly integrated
into mitochondria through the mitochondrial calcium uni-
porter channel complex (mtCU) due to the high electromotive
force generated by the electron transport chain (ETC) (Δψ=
~−160 mv)14. mCa2+ directly impacts cellular bioenergetics
through the activation of dehydrogenases in the TCA cycle and
by modulating ETC function15–17. This is intriguing as alterations
in metabolism are reported to be essential to cell fate determi-
nation, i.e., pluripotency vs. committed/specified cells18–20.
Indeed, alterations in the levels of various metabolites have been
linked to the activity of epigenetic-modifying enzymes, providing
a direct link between cellular metabolism and gene
expression18,20.
Here, we investigate the role of mCa2+ uptake in cellular dif-
ferentiation. This study reveals that alterations in mCa2+
exchange, via MICU1-dependent mtCU gating, is a central reg-
ulatory mechanism linking canonical signaling pathways with
adaptive changes in mitochondrial metabolism and epigenetics
that are necessary to drive cellular differentiation.
Results
Ablation of mCa2+ uptake in fibroblasts. To examine the con-
tribution of mCa2+ uptake to myofibroblast differentiation, we
conditionally deletedMcu, the pore-forming subunit of the mtCU
that is necessary for mCa2+ uptake (Fig. 1a)17,21–23. Mouse
embryonic fibroblasts (MEFs) were isolated from E13.5 Mcufl/fl
embryos and transduced with adenovirus-encoding Cre recom-
binase (Ad-Cre) or beta-galactosidase (Ad-βgal, adenoviral con-
trol) for 24 h, and 4 days later cell lysates were analyzed by
Western blot. Cre-mediated deletion of exons 5–6 caused com-
plete loss of MCU protein (Fig. 1c). We also observed a loss of
mtCU components MCUB and EMRE (Fig. 1c), likely attributed
to protease mediated degradation of the other structural/channel-
forming mtCU components24. Voltage-dependent anion channel
(VDAC) and the UQCRC2 (Ubiquinol-cytochrome-c reductase
complex core protein 2) subunit of Complex III (CIII) were used
as mitochondrial loading controls and tubulin served as a total
lysate loading control. Next,Mcufl/fl MEFs were infected with Ad-
Cre or Ad-βgal and 72 h later transduced with adenovirus
encoding a mitochondrial-targeted genetic Ca2+ reporter (Mito-
R-GECO) for 48 h. Prior to live-cell imaging, cells were loaded
with the calcium sensitive dye Fluo-4 AM to measure cytosolic
calcium (cCa2+) transients. After baseline recordings, cells were
treated with ATP to initiate purinergic receptor-mediated IP3R
Ca2+ release. Control MEFs (Ad-βgal) displayed robust mCa2+
transients, whereas Mcu−/− MEFs (Ad-Cre) displayed complete
loss of mCa2+ uptake (Fig. 1d, e). Further, loss of MCU-mediated
uptake elicited a significant increase in cCa2+ transients, sug-
gesting that mitochondria buffer cCa2+ signaling in fibroblasts
(Fig. 1f, g). In addition, loss of mCa2+ uptake enhanced cytosolic
signaling. Using an adenovirus-encoding NFATc1-GFP, we
measured nuclear translocation of NFATc1 following fibrotic
stimuli. NFATc1 normally resides in the cytoplasm, but upon
increased cCa2+ NFATc1 is dephosphorylated and translocates
into the nucleus to regulate gene transcription25. Treatment with
TGFβ or AngII for 24 h induced nuclear translocation of NFATc1
in control cells (Ad-βgal) and this was slightly potentiated in
Mcu−/− fibroblasts (Ad-Cre) (Supplementary Fig. 1a, b).
Loss of mCa2+ uptake promotes myofibroblast differentiation.
To determine the role of mCa2+ signaling in myofibroblast dif-
ferentiation, Mcufl/fl MEFs were infected with Ad-Cre or Ad-βgal
and 5 days later treated with TGFβ or AngII. MEFs were exam-
ined for differentiation into a myofibroblast by quantifying
α-smooth muscle actin (α-SMA) stress fiber formation, the pro-
totypical marker of myofibroblasts3. Mcu−/− MEFs (Ad-Cre)
displayed increased myofibroblast formation at baseline (vehicle)
and following 24 h TGFβ or AngII treatment as evidenced by an
increase in the percentage of α-SMA+ cells and a ~4-fold increase
in α-SMA expression vs. controls (Ad-βgal) (Fig. 1h–l). Func-
tionally, Mcu−/− MEFs displayed increased contraction of col-
lagen gel matrices, even without TGFβ or AngII treatment,
indicative of enhanced acquisition of the myofibroblast pheno-
type (Fig. 1m, n). We also observed that loss of mtCU-mediated
Ca2+-uptake alone was sufficient to increase expression of key
myofibroblast genes including: collagens (Col1a1 and Col3a1), α-
SMA (Acta2), periostin (Postn), fibronectin (Fn1) and
platelet derived growth factor receptor alpha (Pdgfra) (Fig. 1o).
Importantly, the observed enhancement in Mcu−/− α-SMA+
cells and gel contraction was not due to increased proliferation.
Mcu−/− MEFs showed significantly reduced proliferation
rates, as measured by DNA content, which is also characteristic of
a more differentiated cell type (Fig. 1p). Collectively, these data
show that loss of mCa2+ uptake promotes myofibroblast
differentiation.
Fibrotic stimuli alter mtCU gating to reduce mCa2+ uptake.
Given the significant impact that loss of mCa2+ uptake had on
myofibroblast formation we next examined if acute fibrotic sig-
naling directly altered mtCU function. First, we used live cell
imaging to measure Ca2+ transients in WT fibroblasts incubated
with or without TGFβ for 12 h. MEFs were transduced with Mito-
R-GECO for 48 h and loaded with Fura-2 prior to imaging to
measure mCa2+ and cCa2+ transients in response to ATP-
stimulated IP3R Ca2+ release. TGFβ pretreated cells showed
significantly increased cCa2+ and significantly decreased total
mCa2+ load (Fig. 2a, b, Supplementary Fig. 2a, b).
Next, we measured the impact of acute TGFβ signaling on
mCa2+ uptake in a permeabilized cell system. This high-fidelity
system allows careful monitoring of uptake independent of
changes in other calcium transport mechanisms. After treating
WT MEFs with TGFβ for 12 h, fibroblasts were permeabilized
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Fig. 1 Loss of mCa2+ uptake enhances the myofibroblast differentiation. a Mcu conditional allele with LoxP sites flanking exons 5–6. b Experimental timeline for
deletion of Mcu in mouse embryonic fibroblasts (MEFs). MEFs were isolated from Mcufl/fl embryos at E13.5 and infected with adenovirus encoding Cre
recombinase (Ad-Cre) or the control beta-galactosidase (Ad-βgal) for 24 h. c Expression of mtCU components was examined by Western blot in Mcu−/− (Ad-
Cre) and control (Ad-βgal) MEFs. MICU1 Mitochondrial Ca2+ Uptake 1, MCUR1 Mitochondrial Ca2+ Uniporter Regulator 1, MCUB Mitochondrial Ca2+ Uniporter
B, EMRE Essential MCU Regulator. Mitochondrial loading controls: Voltage-dependent anion channel (VDAC) and complex III (CIII, subunit-UQCRC2) served as
mitochondrial loading controls and tubulin as total lysate loading control. d Mcu−/− and control were transduced with adenovirus encoding the mitochondrial
calcium sensor, Mito R-GECO. 1mM ATP was delivered to initiate IP3R-mediated Ca2+ release; n= 13 cells. e Amplitude (peak intensity–baseline). fMcu−/− and
control were loaded with the Ca2+-sensitive dye Fluo-4 AM. Fluorescence was recorded during 1mM ATP treatment; n= 15 cells Ad-βgal, n= 17 cells Ad-Cre.
g Amplitude (peak intensity–baseline). h–lMEFs were treated with TGFβ or AngII for 24 h and immunofluorescence was performed by costaining with α-smooth
muscle actin (α-SMA) antibody (red) and DAPI (blue); n= 3. h–j Representative images. k Percentage of α-SMA positive cells. l α-SMA expression (fluorescence
intensity). m, n Collagen gel contraction assay; n= 4 Ad-βgal, n= 5 Ad-Cre.m Representative images. n Gel contraction calculated as percent change from time
0 h. o Fold change in expression of myofibroblast genes (vs. Ad-βgal control). Col1a1 collagen type I alpha 1 chain, Col1a2 collagen type I alpha 2 chain, Col3a1
collagen type III alpha 1 chain, α-SMA (Acta2) α-smooth muscle actin, Postn periostin, Lox lysyl oxidase, Fn1 fibronectin 1, Pdgfra platelet derived growth factor
receptor alpha col1a1 (n= 7), col1a2 (n= 4), col3a1 (n= 5), aSMA (n= 5), Postn (n= 9), Lox (n= 6), Fn1 (n= 6), Pdgfra (n= 6). p Cell proliferation measured
by quantifying DNA content; n= 6. Ca2+ traces: solid line=mean, dashed line= SEM. Data shown as mean ± SEM. ***p < 0.001, **p <0.01, *p < 0.05 vs. vehicle
control analyzed by ANOVA. ###p < 0.001, ##p < 0.01, #p < 0.05 vs. Ad-βgal analyzed by t-test. Scale bar= 50 μm. Also see Supplementary Fig. 1
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with digitonin, in the presence of thapsigargin (SERCA inhibitor to
prevent ER Ca2+ uptake) and CGP-37157 (NCLX inhibitor to
block mCa2+ efflux), and loaded with the Ca2+ sensor Fura-2 for
ratiometric monitoring using a spectrofluorometer. An increase in
Fura-2 signal signifies an increase in bath Ca2+ and a decrease in
Fura-2 signal after each bolus represents mCa2+ uptake. TGFβ-
treated fibroblasts displayed a decrease in mCa2+ uptake following
the delivery of ~0.25–2 µM [Ca2+] (representative trace shown in
Fig. 2c). Importantly, simultaneous monitoring of mitochondrial
membrane potential (Δψ) using the ratiometric reporter, JC-1,
showed no difference in the driving force for uptake (Fig. 2d). After
calibration of the Fura-2 reporter (Supplementary Fig. 2c),
we quantified the percentage of mCa2+ uptake over a range of
bath Ca2+ concentrations and data points were fit to the Hill
equation using a nonlinear least-squares fit. From the dose response
curve, we observed the nonlinear nature of mtCU-mediated mCa2+
uptake, consistent with other reports (Fig. 2e)26–28. TGFβ treatment
for 12 h shifted the dose-response curve to the right, demonstrating
an increase in the [Ca2+] threshold for mCa2+ uptake (Fig. 2e, f).
The calculated Kd value was ~1.5 μM in control cells and ~1.9 μM
in TGFβ-treated cells, indicating that following TGFβ higher
[cCa2+] was needed to achieve 50% maximal mtCU uptake
(Fig. 2g). In addition, the Hill coefficient identified a difference in
the slopes of the dose response curves (Fig. 2g), 4.29 in control cells
vs. 10.27 in TGFβ-treated cells, demonstrating that TGFβ indeed
enhanced mtCU gating, allowing virtually no uptake until a given
threshold was reached.
To probe the mechanism responsible for TGFβ-induced
alterations in mCa2+ uptake, we treated WT fibroblasts
with TGFβ and 12, 24, 48, and 72 h later extracted protein to
examine expression of mtCU components. Western blot analysis
revealed a dramatic increase in MICU1 expression 12 h after
treatment (Fig. 2h, i). CIII (subunit UQCRC2) and VDAC
served as mitochondrial loading controls and tubulin served as a
total lysate loading control. Since the MICU1/MCU
ratio underlies tissue-specific differences in the mtCU [cCa2+]
threshold of uptake29, we quantified the relative change in
MICU1/MCU ratio. TGFβ treatment rapidly increased the
MICU1/MCU ratio (Fig. 2j). We also observed a similarly large
increase in MICU1 expression in MEFs treated with AngII
(Fig. 2m–o), suggesting this is a conserved mtCU regulatory
mechanism during myofibroblast differentiation. The substantial
increase in the MICU/MCU ratio is in agreement with our
observed change in mCa2+ uptake following TGFβ treatment and
is consistent with other reports ascribing that MICU1 is a
gatekeeper restricting mtCU-mediated Ca2+ uptake at signaling
levels of [cCa2+]28,30. We propose that profibrotic agonists signal
to acutely upregulate MICU1 expression to inhibit mCa2+ uptake
and initiate myofibroblast differentiation signaling. The relative
expression of additional mtCU components was also quantified
(Supplementary Fig. 2d–k). This increase in MICU1 protein
expression is likely due to TGFβ-mediated and AngII-mediated
transcriptional upregulation of Micu1 (Fig. 2k, p) that occurs as
early as 1 h following stimulation. Neither TGFβ or AngII
induced a change in MCU expression (Supplementary Fig. 2l, n).
Increases in the MICU1/MCU ratio were also evident at the
transcriptional level (Supplementary Fig. 2m, o). We found the
same phenomenon in mouse adult cardiac fibroblasts (ACFs)
treated with TGFβ and AngII-upregulation of MICU1 and an
increase in the MICU1/MCU ratio (Fig. 2l, q, Supplementary
Fig. 2p–s).
TGFβ/AngII signaling elicits dynamic changes in fibroblast
metabolism. cCa2+ is integrated into the mitochondrial matrix
via the mtCU, a mechanism theorized to integrate cellular
demand with metabolism and respiration17,31–33. Further, meta-
bolic reprogramming is required for numerous cellular differ-
entiation programs19,20 and recent studies suggest that enhanced
glycolysis promotes fibroblast differentiation34,35. This prompted
us to examine metabolic changes in glycolysis and oxidative
phosphorylation during myofibroblast differentiation. Mcufl/fl
MEFs were transduced with Ad-Cre or Ad-βgal and 5 days later
treated with TGFβ or AngII for 12, 24, 48, or 72 h, followed by
measurement of extracellular acidification rates (ECAR, glyco-
lysis) and oxygen consumption rates (OCR, OxPhos) using a
Seahorse XF96 analyzer (Supplementary Fig. 3a–c). TGFβ elicited
a significant increase in basal respiration (~135% increase from
baseline) and glycolysis (>400% increase from baseline) peaking
48 h after treatment (Fig. 3a, c). AngII likewise caused a rapid
increase in glycolysis (45% increase from baseline), peaking ~12
h; however, AngII caused a slight decrease in basal respiration
(Fig. 3b, d). Interestingly, loss of MCU (Ad-Cre) further
enhanced the increased glycolysis induced by both TGFβ and
AngII >2-fold, as compared to control (Ad-βgal) (Fig. 3e). Other
Seahorse metabolic parameters under all conditions are reported
in Supplementary Fig. 3d–g.
Next, using a quantitative metabolomics approach, concentra-
tions of fibroblast metabolites were quantified by mass spectro-
metry in Mcu−/− (Ad-Cre) and control (Ad-βgal) fibroblasts at
baseline and 12 h post-TGFβ. These data supported that TGFβ-
dependent changes in mtCU gating mediated the increase in
glycolysis observed by Seahorse analysis. Mcu−/− MEFs (Ad-Cre)
displayed higher levels of the glycolytic intermediates: glucose-6-
phosphate (G-6-P), fructose-6-phosphate (F-6-P), fructose-1,6-
bisphosphate (F-1,6-BP), glyceraldehyde-3-phosphate (GA3P),
dihydroxyacetone phosphate (DHAP) and glycerol-3-phosphate
(G-3-P) (Fig. 3f–m). Importantly, F-1,6-BP, the glycolytic
intermediate produced in the first committed step of glycolysis,
was significantly increased following TGFβ treatment and
this increase was potentiated by loss of MCU (Ad-Cre) (Fig. 3i).
F-1,6-BP is metabolized into GA3P and DHAP, and concentra-
tions of these metabolites followed a similar trend with an
increase post-TGFβ, which was similarly potentiated by loss the
loss of mCa2+ uptake (Fig. 3j, l). In addition to energy production,
glycolysis supplies metabolic intermediates for ancillary biosyn-
thetic pathways necessary for cellular growth and differentiation.
For example, the pentose phosphate pathway (PPP) generates
ribulose-5-phosphate (Ru-5-P) along with NADPH, which are
critical for nucleotide and fatty acid/phospholipid synthesis,
respectively (Supplementary Fig. 4a)36. Following TGFβ, Mcu−/−
MEFs exhibited increased levels of 6-phosphogluconate (6-PG),
Ru-5-P, and ribose-5-phosphate (R-5-P) compared to vehicle
treated controls (Supplementary Fig. 4b–d).
To determine the necessity of enhanced glycolytic flux on
myofibroblast formation, we modulated a rate-limiting enzyme of
glycolysis, phosphofructokinase 1 (PFK1). PFK1 is allosterically
activated by fructose-2,6-bisphosphate (F-2,6-BP), the levels of
which are regulated by the bifunctional enzyme phosphofructo-
kinase 2 (PFK2)/fructose bisphosphatase 2 (FBP2) (Fig. 3f)37.
Employing adenoviruses encoding a phosphatase-deficient PKF2/
FBP2 mutant (S32A, H258A; Ad-Glyco-High) or kinase-deficient
PFK2/FBP2 mutant (S32D, T55V; Ad-Glyco-Low) we examined
the impact of modulating glycolytic rates during myofibroblast
differentiation (Fig. 3n, o)38,39. The PFK2/FBP2 mutant adeno-
viruses also encoded GFP driven by a separate CMV promoter,
allowing identification of transduced cells apart from uninfected
fibroblasts. Ad-Glyco-High expression increased glycolysis in
both control (Ad-βgal) and Mcu−/− (Ad-Cre) MEFs, while Ad-
Glyco-Low expression inhibited the increased glycolysis observed
in Mcu−/− MEFs (Fig. 3p). Control and Mcu−/− MEFs were
infected with either Ad-Glyco-High or Ad-Glyco-Low and 24 h
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later treated with TGFβ or AngII for 24 h followed by
quantification of α-SMA+ cells by immunofluorescence. Enhan-
cing glycolysis was sufficient to drive myofibroblast formation
(Fig. 3q, r) and potentiated cellular differentiation elicited by
TGFβ and AngII (Fig. 3q, r). Inhibition of glycolysis (Ad-Glyco-
Low) prevented TGFβ-mediated and AngII-mediated differentia-
tion and reverted the enhanced differentiation in Mcu−/−
fibroblasts back to control levels (Fig. 3s, t).
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Next, we evaluated mitochondrial metabolism since it is well
established that mCa2+ signaling directly impacts TCA cycle
intermediates by the modulation of pyruvate dehydrogenase
(PDH) and α-ketoglutarate dehydrogenase (αKGDH) activity.
mCa2+ activates PDH phosphatase (PDP1), which dephosphor-
ylates the PDH E1α subunit and thereby increases PDH activity
to convert pyruvate to acetyl-CoA40. Western blot analysis of
phosphorylated PDH (p-PDH E1α, inactive) revealed signifi-
cantly increased p-PDH E1α/PDH in Mcu−/− MEFs (Ad-Cre) at
baseline compared to controls (Ad-βgal) (Fig. 4b, c). Further,
both TGFβ and AngII increased the ratio of p-PDH E1α/PDH,
which was potentiated in Mcu-null fibroblasts (Fig. 4d). Accord-
ingly, metabolomics analysis revealed that TGFβ increased
pyruvate by ~60%, consistent with inhibition of PDH (Fig. 4e).
Mcu−/− MEFs had increased pyruvate at baseline and following
TGFβ compared to controls (Fig. 4e). Acetyl-CoA was decreased
in Mcu−/− MEFs at baseline, also consistent with inactive PDH
(Fig. 4f). Following TGFβ, acetyl-CoA increased in Mcu−/−
MEFs, but did not change in control cells (Fig. 4f). Nonetheless,
acetyl-CoA levels were 100 times lower than pyruvate levels,
suggesting that pyruvate was not entering the TCA cycle via
PDH. Consistent with reduced glucose/pyruvate oxidation, citrate
levels were significantly reduced following TGFβ (Fig. 4g).
Interestingly, TGFβ increased α-ketoglutarate (αKG (Fig. 4h).
Further, Mcu−/− fibroblasts exhibited increased αKG at baseline
and following treatment with TGFβ, as compared to controls
(Fig. 4h). Other TCA cycle intermediates succinate, fumarate, and
malate were unchanged by TGFβ or loss of MCU (Fig. 4i–k).
Reduced glucose-dependent TCA flux increases anaplerotic
elevations in αKG via glutaminolysis41,42. TGFβ decreased
glutamine (Gln) and glutamate (Glu) levels in control cells and
Mcu−/− fibroblasts displayed an increase in the αKG/Gln ratio at
baseline and after TGFβ stimulation (Fig. 4l–n), suggesting that
TGFβ activates glutaminolysis to increase cellular levels of αKG.
All other metabolite concentrations are reported in Supplemen-
tary Fig. 5 and Supplementary Table 1.
To directly test the significance of glutamine utilization in
myofibroblast differentiation, we diminished glutaminolysis in
WT MEFs treated with or without TGFβ for 48 h and assessed α-
SMA formation by immunofluorescence. Glutaminolysis was
constrained by either removal of Gln from media (Fig. 4o–q) or
treatment with CB-839 (Fig. 4r–t). CB-839 is a potent selective
inhibitor of glutaminase 1 (GSL1), the enzyme which converts
Gln into Glu in the first step of glutaminolysis (Fig. 4a)43. In both
of these experiments myofibroblast differentiation was signifi-
cantly attenuated, suggesting that myofibroblast differentiation is
dependent on glutamine-derived αKG (Fig. 4o–t).
Chromatin remodeling activates the myofibroblast gene pro-
gram. αKG is a cofactor for several dioxygenases, including the
epigenetic modifiers ten-eleven translocation enzymes (TETs)
and Jumonji-C (JmjC)-domain-containing demethylases (JmjC-
KDMs), which demethylate DNA cytosine residues and histone
lysine residues, respectively (Fig. 5a)44. We hypothesized that the
observed increase in αKG following TGFβ or loss of MCU altered
epigenetic signaling to promote myofibroblast differentiation. We
assessed global DNA methylation by ELISA in Mcu−/− (Ad-Cre)
and control (Ad-βgal) MEFs at baseline and following treatment
with TGFβ. We observed slight, but non-significant, decreases in
global DNA methylation with TGFβ and loss of MCU (Fig. 5b).
Subsequently, Mcu−/− (Ad-Cre) and control (Ad-βgal) MEFs
were treated with TGFβ and cell lysates were examined for his-
tone 3 (H3) lysine (K) methylation at key residues regulated by
JmjC-KDMs – H3K27, H3K9, and H3K4 (Fig. 5c). Fibroblasts
treated with TGFβ exhibited a progressive decrease in dimethy-
lation of H3K27 (H3K27me2) over time (Fig. 5c, d). Mcu−/−
MEFs exhibited less dimethylation at baseline and post-TGFβ
compared to controls (Fig. 5c, d). Quantification of other
methylation residues is reported in Supplementary Fig. 6a–e.
H3K27me2 is implicated in regulating cell fate by preventing
inappropriate enhancer activation45 and generally is associated
with heterochromatin and gene suppression46.
To directly examine the role of H3K27me2 in controlling the
myofibroblast gene program, we immunoprecipitated chromatin
using an H3K27me2-specific antibody and ChIP’d DNA was
analyzed by qPCR in key regulatory promoter regions of Postn
and Pdgfra, genes, which are early and robust indicators of
fibroblast activation4,47,48. In control cells (Ad-βgal), H3K27me2
was enriched at the Postn and Pdgfra loci and these marks were
lost after 12 h of TGFβ with a concordant increase in mRNA
expression (Fig. 5e, f and Supplementary Fig. 6f, g). Furthermore,
Mcu−/− MEFs (Ad-Cre) exhibited a lack of H3K27me2
enrichment at the Postn and Pdgfra promoters at baseline, which
we hypothesize underlies the enhanced expression of these genes
and suggests Mcu−/− cells are primed for myofibroblast
formation (Fig. 5e, f and Supplementary Fig. 6f, g). Importantly,
binding sites for transcription factors known to be prominent
drivers of myofibroblast differentiation such as serum response
factor (SRF), SMAD family member 3 (SMAD3), nuclear factor
for activated T-cells (NFAT), and myocyte enhancer factor-2
(MEF2) were predicted by MatInspector to be flanked by, or in
close approximation, to the regulatory regions probed by our
qPCR primer sets (Fig. 5e and Supplementary Fig. 6f).
To further examine the role of TGFβ in transcriptional
regulation and chromatin structure, we used the assay for
Fig. 2 Profibrotic stimuli alter mtCU gating to reduce mCa2+ uptake. a MEFs plus or minus (+/−) 12 h TGFβ were loaded with Ca2+-sensitive dye Fura-2.
Fluorescence was recorded and 1 mM ATP was delivered to initiate IP3R-mediated Ca2+ release. Cytosolic Ca2+ (cCa2+) load was determined by
calculating area-under-the-curve (AUC) of cCa2+ transients; n= 28 cells. b MEFs +/− 12 h TGFβ were transduced with adenovirus encoding the
mitochondrial calcium (mCa2+) sensor, Mito-R-GECO. Fluorescence was recorded during 1 mM ATP treatment. mCa2+ load was determined by calculating
AUC; n= 24 cells. c–g MEFs +/− 12 h TGFβ were permeabilized with digitonin in the presence of thapsigargin (SERCA inhibitor) and CGP-37157 (NCLX
inhibitor) and loaded with Ca2+ sensor Fura-2 and Δψ sensor JC-1 for ratiometric monitoring during Ca2+ additions. c Representative Ca2+ traces in
untreated (black) and TGFβ-treated (blue) MEFs. d JC-1 derived Δψ in untreated (black) and TGFβ-treated (blue) MEFs. e, f Dose response curve of mCa2+
uptake following different [Ca2+] boluses. g Kinetic parameters derived from data in panel e. h–j MEFs were treated with TGFβ and cell lysates were
immunoblotted for components of the mtCU, including pore forming subunit MCU and regulatory subunits MICU1 (Mitochondrial Ca2+ Uptake 1), MCUR1
(Mitochondrial Ca2+ Uniporter Regulator 1), MCUB, and EMRE (Essential MCU Regulator), as well as OxPhos Complexes CV (ATP5A) and CIII (subunit-
UQCRC2), VDAC (Voltage-dependent anion channel), and tubulin. Mitochondrial loading controls: VDAC and CIII; total lysate loading control: tubulin.
Band density was normalized to CIII; n= 3. k, lMEFs and mouse adult cardiac fibroblasts (ACFs) were treated with TGFβ andMicu1mRNA was analyzed by
qPCR. n= 6. m–o MEFs were treated with AngII and cell lysates were immunoblotted for MCU, MICU1, MCUR1, MCUB, and EMRE, as well as OxPhos
Complexes CV and CIII, VDAC, and tubulin. Mitochondrial loading controls: VDAC and CIII. Total lysate loading control: tubulin. Band density was
normalized to CIII; n= 3. p, qMEFs and mouse ACFs were treated with AngII andMicu1mRNA was analyzed by qPCR (n= 6). Data shown as mean ± SEM.
***p < 0.001, **p < 0.01, *p < 0.05 vs. vehicle control analyzed by ANOVA. Also see Supplementary Fig. 2
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12103-x
6 NATURE COMMUNICATIONS |         (2019) 10:4509 | https://doi.org/10.1038/s41467-019-12103-x | www.nature.com/naturecommunications
transposase-accessible chromatin utilizing deep-sequencing
(ATAC-seq)49, coupled with RNA sequencing (RNA-seq) in the
same samples, to analyze chromatin accessibility and gene
expression in control and TGFβ-treated MEFs, respectively.
MEFs treated with TGFβ exhibited enhanced chromatin acces-
sibility in the transcriptional regulatory region of key
myofibroblast genes including: Postn (Fig. 5g), Acta2 (α-SMA),
Pdgfra, Col1a1, Lysyl Oxidase (Lox), Tgfβ, and Wnt family
member 1 (Wnt1) (Supplementary Fig. 7a–f). Importantly,
ATAC-derived increases in open chromatin structure correlated
with increased or decreased mRNA transcription in a direction-
ality in agreement with what has been reported for myofibroblast
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formation47. Furthermore, these enhanced accessible regions
contained binding sites for known pioneer transcription factors
associated with fibroblast activation (example: Fig. 5e).
To determine the physiological relevance of αKG-dependent
histone demethylation on myofibroblast differentiation we
incubated MEFs in media containing cell-permeable dimethyl-
αKG (DM-αKG) +/− TGFβ for 48 h and assessed α-SMA
expression by immunofluorescence. Strikingly, DM-αKG
increased the percentage of α-SMA positive cells to the same
extent as 48 h of TGFβ treatment (Fig. 5h–j). Finally, we
examined the effect of JIB-04, a cell-permeable inhibitor of
JmjC-KDMs, on myofibroblast differentiation. JIB-04 is a
selective inhibitor of specific JmjC-KDMs (Fig. 5k)50, including
JMJD3 (KDM6B gene), which demethylates H3K27me2/351.
Mcufl/fl MEFs were transduced with Ad-Cre or Ad-βgal and
5 days later treated with TGFβ +/− 1 μM JIB-04 for 24 h and α-
SMA expression was measured by immunofluorescence. Treat-
ment with JIB-04 attenuated TGFβ-induced myofibroblast
differentiation and inhibited the increased percentage of α-SMA
positive cells observed in Mcu−/− MEFs (Fig. 5l–o). Altogether,
these data demonstrate that TGFβ-induced metabolic changes
lead to increased αKG levels and subsequent demethylation of
repressive H3K27me2 chromatin marks to allow for coordinated
genetic reprogramming and myofibroblast differentiation.
Adult deletion of fibroblast Mcu worsens cardiac fibrosis after
injury. To directly examine myofibroblast differentiation in vivo,
Mcufl/fl mice were crossbred with a fibroblast-specific (Col1a2 cis-
acting fibroblast-specific enhancer with minimal promoter),
tamoxifen (tamox)-inducible Cre transgenic mouse (Col1a2-
CreERT) (Fig. 6a). The Col1a2-CreERT transgenic mice only
expresses Cre in the fibroblast population in genetic fate mapping
experiments52. Following tamoxifen administration, cardiac
fibroblasts isolated from Mcufl/fl × Col1a2-CreERT adult mice
showed a near complete loss of MCU (Fig. 6b). CIII (subunit
UQCRC2) was used as a mitochondrial loading control. We
evaluated the role of cardiac fibroblast MCU using two in vivo
models known to promote myofibroblast formation and cardiac
fibrosis–myocardial infarction (MI) and chronic infusion of
AngII.
MI results in significant cell death, initiating myofibroblast
differentiation to generate a fibrotic scar to replace lost
myocytes6. Mice were injected intraperitoneal (i.p.) with tamox
(40 mg/kg) for 10 days followed by a 10 day rest period before
acquisition of baseline echocardiography. One week later mice
underwent surgical ligation of the left coronary artery (LCA) to
induce a large MI and left ventricular (LV) structure and function
was tracked weekly by echocardiography (Fig. 6c). In both
experimental and control groups, MI induced significant cardiac
dysfunction and this was exacerbated in Mcufl/fl × Col1a2-
CreERT mice (Fig. 6d–f). Loss of fibroblast MCU (Mcufl/fl ×
Col1a2-CreERT) significantly increased LV dilation, evident by
increased LV end-diastolic diameter (LVEDD) and end-systolic
diameter (LVESD), as well as reduced fractional shortening (FS)
2–4 weeks post-MI, as compared to Col1a2-CreERT controls
(Fig. 6d–f). All other echocardiographic parameters are reported
in Supplementary Fig. 8a–c and Supplementary Table 2. Loss of
fibroblast MCU significantly increased heart weight to tibia length
ratios (HW/TL) and lung edema (wet–dry lung weight) 4 weeks
post-MI, suggesting an increase in hypertrophy and/or edema
and inflammation, both of which are associated with fibrosis
(Fig. 6g, h)7. Masson’s trichrome staining of mid-ventricle cross-
sections revealed increased collagen deposition in Mcufl/fl ×
Col1a2-CreERT mice compared to Col1a2-CreERT controls
(Fig. 6i). Quantification of fibrosis in the border and remote
zones revealed a more than 2.5-fold increase in Mcufl/fl × Col1a2-
CreERT hearts vs. Col1a2-CreERT controls (Fig. 6j). Importantly,
the increased fibrosis was associated with enhanced myofibroblast
formation, which we assessed by immunofluorescence staining
for α-SMA and CD31 (PECAM-1, marker of endothelial cells).
Using this technique, blood vessels/smooth muscle cells costain
with α-SMA and CD31, while myofibroblasts only stain with α-
SMA (Supplementary Fig. 8d)47.Mcufl/fl × Col1a2-CreERT hearts
displayed increased myofibroblast number compared to Col1a2-
CreERT controls in the remote zone 4 weeks post-MI (Fig. 6k).
To further define the centrality of mCa2+ exchange in
myofibroblast formation we employed AngII-infusion as a second
model of fibrosis. AngII is a direct stimulus of myofibroblast
formation, and neurohormonal stress resulting from chronic
increases in AngII levels is documented to induce cardiac fibrosis
both clinically and experimentally53. Mice were injected i.p. with
tamox (40 mg/kg) for 10 days followed by a 10 day rest period
before subcutaneous implantation of Alzet mini-osmotic pumps
to deliver AngII (1.1 mg/kg/day) for 4 weeks (Fig. 6l). Mice
were sacrificed after 4 weeks and hearts were fixed and stained
for fibrosis. Masson’s trichrome staining of mid-ventricle
Fig. 3 TGFβ/AngII signaling elicits rapid and dynamic changes in fibroblast metabolism. a–e MEFs were treated with fibrotic stimuli and a Seahorse XF96
analyzer measured extracellular acidification rates (ECAR, glycolysis) or oxygen consumption rates (OCR, OxPhos); n= individual dots/group, 3
experiments per study. a, b Percent change in glycolysis (y-axis) vs. percent change in basal respiration (x-axis) following stimulation with TGFβ or AngII
for 0, 12, 24, or 48 h. c, d Schematic representations of changes in glycolysis (blue) and oxidative phosphorylation (red) during myofibroblast
differentiation induced by TGFβ or AngII. e Quantification of glycolysis 12 h post-TGFβ or post-AngII. Percent change vs. Ad-βgal vehicle. f Outline of
glycolysis depicting the metabolites: glucose-6-phosphate (G-6-P), fructose-6-phosphate (F-6-P), fructose-1,6-bisphosphate (F-1,6-BP), fructose-2,6-
bisphosphate (F-2,6-BP), dihydroxyacetone phosphate (DHAP), glycerol-3-phosphate (G-3-P), glyceraldehyde-3-phosphate (GA3P), 1,3-
bisphosphoglyceric acid (1,3-BPG), 3-phosphoglyceric acid (3-PG), and the enzymes: phosphofructokinase 2/fructose bisphosphatase 2 (PFK2/FBP2),
phosphofructokinase 1 (PFK1). veh (n= 15), TGFβ (n= 10), AngII (n= 8) g–m Absolute concentration of glycolytic intermediates in Mcu−/− (Ad-Cre) and
control (Ad-βgal) MEFs at baseline and 12 h post-TGFβ. n= 3. n, o Adenoviruses co-expressing mutant PFK2/FBP2 and GFP: phosphatase-deficient PFK2/
FBP2 (S32A, H258A; Ad-Glyco-High) or kinase-deficient PFK2/FBP2 (S32D, T55V; Ad-Glyco-Low). p Mcu−/− and control MEFs transduced with Ad-
Glyco-High, Ad-Glyco-Low, or control Ad-GFP and 24 h later assayed for glycolysis by measuring ECAR; Ad-bgal + Ad-GFP (n= 14), Ad-bgal + Ad-Glyco-
High (n= 11), Ad-bgal + Ad-Glyco-Low (n= 9), Ad-cre + Ad-GFP (n= 14), Ad-cre + Ad-Glyco-High (n= 13), Ad-cre + Ad-Glyco-Low (n= 16) q, r MEFs
were transduced with Ad-Glyco-High and 24 h later treated with TGFβ or AngII for 24 h. Immunofluorescence was performed for α-SMA. Representative
images are presented; white arrows denote α-SMA+/GFP+ cells, i.e., cells infected with Ad-Glyco-High that expressed α-SMA. Percentage of α-SMA
+/GFP+ (Ad-Glyco-High) and α-SMA+/GFP− (Ad-Control) was quantified; n= 3 experiments, >50 cells per group. s, t MEFs were transduced with Ad-
Glyco-Low and 24 h later treated with TGFβ or AngII for 24 h. Immunofluorescence was performed for α-SMA. Representative images are presented; white
arrows denote α-SMA-/GFP+ cells, i.e., cells infected with Ad-Glyco-Low but did not express α-SMA. Percentage of α-SMA+/GFP+ (Ad-Glyco-Low) and
α-SMA+/GFP− (Ad-Control) was quantified; n= 3 experiments, >50 cells per group. All data shown as mean ± SEM. ***p < 0.001, **p < 0.01, *p < 0.05 vs.
vehicle control analyzed by ANOVA. ###p < 0.001, ##p < 0.01, #p < 0.05 vs. Ad-βgal analyzed by t-test. Scale bar= 50 μm. Also see Supplementary Fig. 3
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cross-sections revealed increased collagen deposition throughout
the heart in Mcufl/fl × Col1a2-CreERT mice compared to Col1a2-
CreERT controls (Fig. 6m). Quantification of interstitial fibrosis
revealed a significant increase in Mcufl/fl × Col1a2-CreERT hearts
vs. Col1a2-CreERT controls (Fig. 6n). In addition, chronic AngII
significantly increased myofibroblast formation in Mcufl/fl ×
Col1a2-CreERT hearts vs. Col1a2-CreERT as determined by
α-SMA+/CD31− immunohistochemistry staining (Fig. 6o).
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Discussion
Recently, the mCa2+ field has been transformed by the discovery
of many genes that encode mCa2+ transporters and channels. The
biophysical properties of mtCU-mediated Ca2+ influx have been
extensively studied in many cell types, and the role of mCa2+ as a
regulator of bioenergetics and cell death is well docu-
mented16,17,26,54,55. Here, we link changes in mtCU Ca2+ uptake
and mitochondrial metabolism with epigenetic modulation of the
gene program to drive cellular differentiation. This study provides
evidence that extracellular fibrotic signaling alters mitochondrial
function in order to drive transcriptional changes in the nucleus
necessary for differentiation.
Loss of mCa2+ uptake was sufficient to promote fibroblast to
myofibroblast conversion and enhance the myofibroblast phe-
notype. Fibroblast-specific deletion of Mcu in adult mice aug-
mented myofibroblast formation and fibrosis post-MI and
chronic AngII administration. Further, we found that fibrotic
agonists signal to acutely downregulate mCa2+ uptake by rapidly
increasing expression of the mtCU gatekeeper, MICU1. Although
attributed to another mechanism, TGFβ-mediated reduction of
mCa2+ uptake was also observed in smooth muscle
cells–pretreatment with TGFβ reduced mCa2+ uptake in the face
of increased cCa2+56. Given the noted role of MICU1 to nega-
tively regulate uptake at signaling levels of cCa2+ [<2 µm], we
hypothesize that fibrotic agonists signal to acutely inhibit mCa2+
uptake to initiate myofibroblast differentiation26,28,30,57,58. Our
data suggest that extracellular stimuli are regulating cellular
processes by directly altering mitochondrial signaling. We
hypothesize that modulation of the uniporter is essential for the
coordinated activation of both mitochondrial and cytosolic sig-
naling pathways to mediate cellular differentiation. The outcome
of this is two-fold. In addition to essential changes in mito-
chondrial metabolism upstream of epigenetic reprogramming,
modulation of the mtCU is a way to enhance canonical cytosolic
signaling pathways, hence the slight increase in NFAT activation
(Supplementary Fig. 1).
Examination into mechanisms of pluripotency vs. differentia-
tion has revealed the importance of metabolism, prompting us to
evaluate the relationship between mCa2+ uptake, metabolism, and
myofibroblast differentiation. Fibrotic agonists increased glyco-
lysis and loss of MCU augmented this phenotype. Mechan-
istically, using mutant PFK2/FBP2 transgenes to increase or
decrease glycolysis, we showed that enhanced glycolysis is suffi-
cient to promote differentiation, whereas inhibition of glycolysis
reverted the gain-of-function phenotype noted in Mcu−/−
fibroblasts. This data is consistent with other studies that have
shown glycolytic reprogramming correlates with myofibroblast
differentiation34,35. Glycolytic reprogramming is a well-
substantiated phenomenon which allows for diversion of glyco-
lytic intermediates into ancillary metabolic pathways in order to
generate building blocks for biosynthesis of macromolecules59.
Our data suggest that increased glycolytic flux is necessary to
fulfill cellular anabolic needs, for example nucleotide synthesis, de
novo protein translation, membrane formation, etc., required for
myofibroblast formation. We hypothesize that loss of mCa2+
uptake promoted aerobic glycolysis by reducing the activity of key
Ca2+-dependent enzymes. Indeed the phosphorylation status of
PDH in response to fibrotic agonists and Mcu−/− fibroblasts
suggested inactivity and thereby pyruvate was hindered from
entering the TCA cycle. In correlation with our results, data
obtained from ovarian cancer cell lines showed that MICU1
expression promoted the inhibition of PDH and aerobic
glycolysis60.
Metabolomic analysis revealed a multitude of changes
induced by both TGFβ and the loss of MCU. In addition to
increased levels of pyruvate, consistent with inactive PDH,
metabolite quantification showed increased αKG ~2-fold in
TGFβ-treated fibroblasts and this increase was augmented by
loss of mCa2+ uptake. αKG is not restricted to its role as a TCA
cycle intermediate, but is also a powerful signaling molecule. Of
particular interest is the role of αKG in promoting DNA and
histone demethylation by modulating αKG-dependent TET
enzymes and JmjC-KDMs44. Previous studies have suggested
that αKG regulates the balance between pluripotency and
lineage-commitment of embryonic stem cells (ESCs). αKG
maintained pluripotency of ESCs by promoting JmjC-KDM-
dependent and TET-dependent demethylation, permitting gene
expression to support pluripotency18. Interestingly, αKG also
accelerated the differentiation of primed human pluripotent
stem cells20. TGFβ and loss of MCU induced dynamic changes
in histone lysine methylation at residues regulated by JmjC-
KDMs. Furthermore, TGFβ increased chromatin accessibility at
regions within key myofibroblast genes permitting increased
gene transcription. TGFβ significantly reduced global
H3K27me2 marks and Mcu−/− MEFs displayed reduced
H3K27me2 compared to controls at baseline and post-TGFβ,
suggesting these cells were primed for myofibroblast gene
expression. Importantly, we determined that TGFβ induces the
loss of H3K27me2 at regulatory myofibroblast gene loci (pro-
moter and enhancer regions associated with gene activation and
predicted binding sites for known fibrotic transcription factors).
These data suggest that the observed increase in αKG bioa-
vailability promotes H3K27me2 demethylation at
myofibroblast-specific genes in order to promote differentia-
tion. Further evidence in support of our working hypothesis are
recent reports suggesting that JMJD3, a JmjC H3K27me2
demethylase with loci specificity, i.e., recruitment to lineage-
specific genes, is dependent upon interaction with SMADs61,62.
Since SMAD2/3 is a canonical transcription factor for TGFβ
signaling and myofibroblast activation, it’s intriguing to hypo-
thesize that this interaction may provide myofibroblast-specific
demethylation patterns in our model.
Fig. 4 Loss of mCa2+ uptake reduces pyruvate entry into the TCA cycle. a TCA cycle with emphasis on key mCa2+-control points – pyruvate dehydrogenase
(PDH) and α-ketoglutarate dehyodrogenase (αKGDH). b Mcu−/− (Ad-Cre) and control (Ad-βgal) MEFs were immunoblotted for p-PDH E1α
(phosphorylated pyruvate dehydrogenase, inactivate), total PDH E1α, PDPc (pyruvate dehydrogenase phosphatase catalytic subunit 1), IDH3A
(mitochondrial isocitrate dehydrogenase subunit alpha), GAPDH (glyceraldehyde 3-phosphate dehydrogenase) and tubulin. c Ratio of p-PDH E1α/PDH
E1α; n= 7. d Mcu−/− and control MEFs were treated with TGFβ or AngII for 0, 24, 48, or 72 h and immunoblotted for p-PDH E1α, PDH E1α and OxPhos
Complex V. e–n Absolute concentration of metabolites in Mcu−/− (Ad-Cre) and control (Ad-βgal) MEFs at baseline and 12 h post-TGFβ; n= 3. o–q MEFs
were cultured in media with or without Glutamine (Gln) and treated with TGFβ for 48 h. Immunofluorescence was performed for α-SMA. Representative
images are presented. Percentage of α-SMA+ cells was quantified; n= 3 experiments, >50 cells quantified. r–t MEFs were cultured in media with or
without CB-839, a potent and selective inhibitor of glutaminase 1 (GSL1) (see panel a). Immunofluorescence was performed for α-SMA. Representative
images are presented. Percentage of α-SMA+ cells was quantified; n= 10 each >50 cells quantified. All data shown as mean ± SEM. ***p < 0.001,
**p < 0.01, *p < 0.05 vs. vehicle control analyzed by ANOVA. ###p < 0.001, ##p < 0.01, #p < 0.05 vs. Ad-βgal (panels c–n), vs. –Gln (panel q), vs. CB-839
(panel t) analyzed by t-test. Scale bar= 50 μm
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Since PDH-mediated pyruvate entry into the TCA cycle was
inhibited, we suspect that anaplerotic pathways are being acti-
vated to replenish TCA cycle intermediates, specifically αKG. Our
data suggest that the increased level of αKG associated with dif-
ferentiation is likely generated through the pyruvate carboxylase
pathway and/or glutaminolysis59. Pyruvate carboxylase activity is
documented in cancer cells to mediate glucose-derived pyruvate
to enter the TCA cycle at the level of oxaloacetate63. The second
major replenishment pathway is through glutaminolysis which is
a two-step process that converts glutamine to glutamate to
αKG41,42. Our data suggests this is a more likely scenario, as we
observed an increased αKG/Gln ratio post-TGFβ, and removal of
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glutamine from culture media or pharmacological inhibition of
glutaminase was sufficient to block myofibroblast formation.
In addition to providing carbons to the TCA cycle through
αKG, glutamine metabolism contributes to many other cellular
processes such as nucleotide synthesis, amino acid production,
fatty acid synthesis, and redox modulation64; all cellular processes
that are needed in the differentiating cell. Interestingly, in cancer
cells increases in aerobic glycolytic flux is often associated with
enhanced glutaminolysis41,65. Given the similarities with our
model, it’s intriguing to conjecture that the mtCU may play a
similar role in these cell systems. The physiological relevance of
the mtCU-dependent metabolic shift described here likely
extends beyond epigenetic signaling pathways as wound healing
and fibrosis typically occurs in a hypoxic environment and thus
increased anaerobic glycolysis would be essential for energetic
support in the differentiating fibroblast. However, our causative
experiments downstream of metabolism indicate that this alone
does not account for our phenotype.
In summary, we show that loss of mCa2+ uptake promotes
myofibroblast differentiation both in vitro and in vivo. Until now,
the role of mCa2+ uptake in cellular differentiation or epigenetic
regulation has not been explored, but our study reveals its
importance in myofibroblast differentiation through concerted
alterations in both metabolism and epigenetics. In addition, our
findings support an endogenous role for decreased mtCU-
mediated mCa2+ uptake as an essential element of the differ-
entiation process (Fig. 7). While much work remains to fully
elucidate the role of mtCU during cellular differentiation, our
current study provides a new framework underlying mitochon-
drial signaling and regulation of the epigenome.
Methods
Generation of fibroblast-specific Mcu conditional knockout mice. Generation
of Mcufl/fl was previously reported17. Mcufl/fl mice were crossed with fibroblast-
specific Cre transgenic mice, Col1a2-CreERT, to generate tamoxifen-inducible,
fibroblast-specific Mcu knockouts. For temporal deletion of Mcu, mice 8–12 weeks
of age were injected intraperitoneal with tamoxifen (40 mg/kg/day) for ten con-
secutive days. All mouse genotypes, including controls, received tamoxifen. All
animal work complied with ethical regulations for animal testing and research, and
was done in accordance with IACUC approval by Temple University and followed
all AAALAC guidelines.
Mouse embryonic fibroblast isolation and culture. Mouse embryonic fibroblasts
(MEFs) were isolated from Mcufl/fl or C57/BL6 (WT) mice. Embryos were isolated
from pregnant females at E13.5. The embryos were decapitated and all the red
organs removed. Tissue was minced and digested in 0.25% trypsin supplemented
with DNase for 15 min at 37 °C in the presence of 5% CO2. Digested tissue was
gently agitated by pipetting to dissociate cells. Cells from each embryo were
suspended in Dulbecco’s Modified Eagle's Medium (DMEM, Corning 10-013-CV)
supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products), 1%
penicillin/streptomycin (Sigma), and 1% Non-Essential Amino Acids (Gibco),
plated on a 10 cm dish and incubated at 37 °C in the presence of 5% CO2. In some
experiments MEFs were incubated in media containing dimethyl-αKG (dimethyl 2-
oxoglutarate, Sigma, 349631), JIB-04 (Sigma, SML0808), or CB-839 (Cayman,
1439399-58-2) as indicated in the results and figures. For all imaging studies, MEFs
were plated on collagen-coated 35 mm dishes (Mattek).
Cardiac fibroblast isolation and culture. After euthanasia, hearts were excised
from mice and rinsed with cold Hank’s Balanced Salt Solutions (HBSS,
Corning, MT21023CV). Atria were removed and ventricles were placed into HBSS
containing 150 units/ml of Collagenase Type 2 (Worthington, LS004176) and
0.6 mg/ml Trypsin (USB Corp., 22705). The ventricles were minced into small
pieces to facilitate digestion, transferred to a small beaker and incubated in a
shaking 37 °C water bath for 5 min. The supernatant was aspirated and discarded
and new HBSS/enzyme solution was added to the beaker. Beaker was incubated in
a shaking 37 °C water bath for 15 min and supernatant was collected and trans-
ferred to a conical containing media and FBS. This was repeated at least 3 more
times until remaining pieces were too small to separate from digestion solution.
Cells were spun down at 400×g for 5 min. Supernatant was discarded, pellets were
resuspended in FBS, and spun down at 400×g for 5 min. After centrifugation,
supernatant was discarded and pellets were resuspended in DMEM (Corning 10-
013-CV) supplemented with 10% fetal bovine serum (FBS, Gemini Bio-Products),
1% penicillin/streptomycin (Sigma), and 1% Non-Essential Amino Acids (Gibco).
Resuspended cells were passed through a 70-micron cell strainer, placed into a cell
culture dish, and incubated at 37 °C in the presence of 5% CO2. After ~1 h, media
was removed and replaced with fresh media.
Adenoviral transfer. For experiments that required adenoviral gene transfer,
MEFs were incubated in adenovirus for 24 h at which time the media was changed.
To knockout Mcu, MEFs were transduced with adenovirus encoding Cre-
recombinase (Ad-Cre) or βgalactosidase (Ad-βgal) for 24 h and experiments were
performed 5 days post-infection in order to ensure sufficient time for protein
turnover. For experiments using adenovirus encoding Glyco-High, Glyco-Low, or
mito-R-GECO1, cells were incubated for an additional 24 h prior to the
experiment.
The following adenoviruses have previously been described: NFAT-c1-GFP,
Glyco-High, Glyco-Low, mito-R-GECO138,39,66,67. Glyco-High and Glyco-Low
adenoviruses were made and purified by Vector Labs (Malvern, PA) using cDNA
for a rat liver PFKFB1 isoform of phosphofructokinase 2 (PFK2)/fructose-2,6-
bisphosphatase (FBP2). The Glyco-High adenovirus has 2 single-amino acid point
mutations (S32A and H258A) which result in the enzyme having only PFK2
activity, while the Glyco-Low adenovirus has 2 single-amino acid point mutations
(S32D and T55V) which result in the enzyme having only FBP2 activity38,39. Ad-
GFP was purchased from Vector Labs (Malvern, PA).
Myofibroblast differentiation. Myofibroblast differentiation was induced using
10 ng ml−1 recombinant mouse transforming growth factor-β (TGFβ, R&D Sys-
tems, 7666-MB-005) or 10 µM Angiotensin II (AngII, Sigma A9525). In all
experiments, FBS was reduced to 1% 24 h prior to and during treatment with TGFβ
or AngII.
Western blot analysis. All protein samples were lysed by homogenization in
RIPA buffer supplemented with phosphatase inhibitors (Roche, 4906837001) and
Fig. 5 Loss of mCa2+ uptake drives myofibroblast differentiation through epigenetic reprogramming. a Simplified schematic of the reaction mechanism of α-
ketoglutarate (αKG)-dependent dioxygenases: ten-eleven translocation (TET) enzymes and Jumonji-C (JmjC)-domain-containing demethylases (JmjC-
KDMs). b Levels of 5-methylcytosine (5-mC) were measured in Mcu−/− (Ad-Cre) and control (Ad-βgal) MEFs by ELISA. Fold change vs. Ad-βgal veh.
cMEFs were treated with TGFβ for 0, 12 or 24 h and cell lysates were immunoblotted for specific methylated histone 3 lysine (H3K) residues. Total H3 and
Tubulin were used as loading controls. d Quantification of H3K27me2 protein expression. Band density was normalized to total H3. e H3K27me2
chromatin immunoprecipitation followed by qPCR (ChIP-qPCR) of Periostin in Mcu−/− (Ad-Cre) and control (Ad-βgal) MEFs at baseline (veh) and
following 12 h TGFβ. Schematic shows loci of qPCR primers in relationship to myofibroblast-associated transcription factor binding sites – NFAT (nuclear
factor of activated T-cells), SRF (serum response factor). f Expression of periostin (Postn) mRNA in Mcu−/− (Ad-Cre) and control (Ad-βgal) MEFs at
baseline (veh) and post-TGFβ. g WT MEFs were treated with vehicle or TGFβ and assessed for chromatin accessibility and transcription using ATAC-seq
and RNA-seq. Results of the Postn locus are shown. The height of the genome browser tracks shows the number of reads normalized by read depth and
overall peak enrichment in the library. h–j Wildtype MEFs treated +/− cell-permeable, dimethyl-αKG and +/− TGFβ for 48 h followed by
immunofluorescence for α-SMA. Representative images and quantification of percentage of α-SMA+ cells are shown. k Schematic of JmjC-KDM reactions
indicating the specific JmjC-KDMs inhibited by JIB-04. l–oMcu−/− (Ad-Cre) and control (Ad-βgal) MEFs were treated with vehicle, TGFβ, or TGFβ + 1 μM
JIB-04 for 24 h and immunofluorescence was performed by costaining with α-smooth muscle actin (α-SMA) antibody (red) and DAPI (blue).
Representative images and quantification of percentage of α-SMA+ cells are shown. n= 3 experiments for all quantified data. All data shown as mean ±
SEM. ***p < 0.001, **p < 0.01, *p < 0.05 vs. vehicle control analyzed by ANOVA. ###p < 0.001, ##p < 0.01, #p < 0.05 vs. Ad-βgal analyzed by t-test. +++p <
0.001 TGFβ vs. TGFβ + JIB-04 analyzed by ANOVA. Scale bar= 50 μm
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-019-12103-x
12 NATURE COMMUNICATIONS |         (2019) 10:4509 | https://doi.org/10.1038/s41467-019-12103-x | www.nature.com/naturecommunications
protease inhibitors (Sigma, S8830). Samples were sonicated briefly and centrifuged
at 5000×g for 10 min. The supernatant was collected and used for further analysis.
Protein amount was quantified using the Bradford Protein Assay (Bio-Rad) and
equal amounts of protein (10–50 µg) were run by electrophoresis on poly-
acrylamide Tris-glycine SDS gels. Gels were transferred to PVDF (EMD Millipore,
IPFL00010) and membranes were blocked for 1 h in Blocking Buffer (Rockland,
MB-070) followed by incubation with primary antibody overnight at 4 °C. Mem-
branes were washed in TBS-T 3 times for 5 min each and then incubated with
secondary antibody for 1 h at room temperature. After incubation with fluorescent
secondary antibodies, membranes were washed in TBS-T 3 times for 5 min each
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Fig. 6 Adult deletion of fibroblast Mcu exacerbates cardiac dysfunction, fibrosis, and myofibroblast formation post-MI and chronic angiotensin II
administration. a Mcufl/fl mice were crossed with mice expressing a tamoxifen (tamox)-inducible, fibroblast-specific Cre recombinase (Col1a2-CreERT).
Tamox administration (40mg/kg/day) for 10 days induces fibroblast-restricted Cre expression. b Adult cardiac fibroblasts were isolated post-tamox
treatment and immunoblotted for MCU expression. CIII (Complex III, subunit-UQCRC2) was used as a loading control. c Experimental timeline: 8–12-week-
old mice were treated with tamox and allowed to rest before permanent ligation of the left coronary artery. d–f Cardiac function was analyzed by
echocardiography 1 week prior to MI and every week thereafter. M-mode echo measurements of left ventricular end diastolic diameter (LVEDD), left
ventricular end systolic diameter (LVESD), and percent fractional shortening (FS). n= 10 Col1a2-Cre, n= 20Mcufl/fl × Col1a2-Cre. g Ratio of heart weight to
tibia length 4 weeks post-MI. Sham: n= 5 Col1a2-Cre, n= 7Mcufl/fl × Col1a2-Cre; post-MI: n= 10 Col1a2-Cre, n= 20Mcufl/fl × Col1a2-Cre. h Quantification
of wet–dry lung weight as a measurement of lung edema 4 weeks post-MI. n= 10 Col1a2-Cre, n= 20Mcufl/fl × Col1a2-Cre. i, j LV sections were stained with
Masson’s trichrome (MTc). Representative images are shown. Percent fibrotic area per infarct border and remote zones. n= 4 mice per group, multiple non-
consecutive heart sections were quantified per mouse. k Percent change in myofibroblast number (α-SMA+/CD31−) in the remote zone 4 weeks post-MI.
n= 4 Col1a2-Cre, n= 8 Mcufl/fl × Col1a2-Cre; multiple non-consecutive heart sections in the remote zone were quantified per mouse. l Experimental
timeline: mini-osmotic pumps were subcutaneously implanted in mice to deliver AngII for 4 weeks. m, n Representative images of MTc stained LV sections.
Percent fibrosis per area was quantified. n= 5 Col1a2-Cre, n= 4 Mcufl/fl × Col1a2-Cre; multiple non-consecutive heart sections were quantified per mouse.
o Percent change in myofibroblast number (α-SMA+/CD31−) 4 weeks post-AngII infusion. Sham: n= 3; AngII: n= 4; multiple non-consecutive heart
sections were quantified per mouse. All data shown as mean ± SEM, ***p < 0.001, **p < 0.01, *p < 0.05 vs. control (week 0 or sham) analyzed by ANOVA.
###p < 0.001, ##p < 0.01, #p < 0.05 vs. Ad-βgal analyzed by t-test. Scale bar= 250 μm. Also see Supplementary Fig. 7 and Supplementary Table 2
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and then imaged on a Licor Odyssey system. The following antibodies were used in
the study: MCU (1:1000, Sigma-Aldrich, HPA016480), MCUB (1:250, Santa Cruz,
sc-163985), MICU1 (1:500, Custom generation by Yenzyme, courtesy of the
Madesh lab), MCUR1 (1:500, Custom generation, courtesy of the Madesh lab),
EMRE (1:250, Santa Cruz, sc-86337), VDAC (1:1000, Abcam, ab15895), PDHE1α
phospho S293 (1:1000, Abcam, ab110330), PDHE1α (1:1000, Abcam, ab110330),
IDH3A (1:500, Abcam, ab58641), α-tubulin (1:1000, Abcam, ab7291), ETC
respiratory chain complexes (1:2,500, OxPhos Cocktail, Abcam, MS604),
H3K4me3 (1:2000, Millipore, 07-473), H3K9me3 (1:2000, Abcam, ab8898),
H3K27me3 (1:2000, Cell Signaling, 9733), H3K4me2 (1:2000, Cell Signaling, 9726),
H3K9me2 (1:2000, Cell Signaling, 4658), H3K27me2 (1:2000, Cell Signaling, 9728),
H3 (1:2000, Cell Signaling, 4499); and Licor IRDye secondary antibodies: anti-
mouse (1:12,000, 926–32210), anti-rabbit, (1:12,000, 926–68073), anti-goat
(1:12,000, 926–32214). All full-length Western blots are displayed in Supplemen-
tary Figs. 9–13.
Live cell imaging of Ca2+ transients. Mcufl/fl MEFs were infected with Ad-Cre or
Ad-βgal for 72 h and then transduced with adenovirus encoding a mitochondrial-
targeted Ca2+ reporter (Mito-R-GECO). Forty-eight hours post-infection with
Mito-R-GECO, prior to live-cell imaging, MEFs were loaded with the calcium
sensitive dye Fluo-4 AM (1 μM, Invitrogen) or Fura-2 (1 μM, Invitrogen) to
measure cytosolic calcium transients. Cells were placed in a 37 °C heated chamber
in physiological Tyrode’s buffer (150 mM NaCl, 5.4 mM KCl, 5 mM HEPES,
10 mM glucose, 2 mM CaCl2, 2 mM sodium pyruvate, pH 7.4) and imaged on a
Carl Zeiss Axio Observer Z1 microscope. Ca2+ transients were continuously
recorded and analyzed on Zen software. After 2–3 min of baseline recording, a
single pulse of 1 mM ATP was delivered to liberate intracellular Ca2+ (iCa2+)
stores. Background fluorescence was subtracted from each experiment before cal-
culating the peak intensity as the maximal fluorescence/baseline fluorescence.
Immunofluorescence. MEFs were seeded on coated 35-mm dishes. MEFs were
fixed for 15 min in 4% paraformaldehyde, then permeabilized for 15 min with
0.15% Triton-X-100, and blocked in PBS containing 10% goat serum for 1 h at
room temperature. MEFs were incubated in primary antibody α-SMA (1:1000,
Sigma-Aldrich, A2547) overnight at 4 °C and secondary antibody goat anti-mouse
Alexa Fluor 594 (1:1000, ThermoFisher, A-11005) for 45 min at 37 °C. Prior to
imaging, MEFs were incubated with Hoechst 33342 to demarcate cell nuclei. Cells
were imaged on a Carl Zeiss Axio Observer Z1 fluorescent microscope. Images
were acquired in the red (590ex/617em) and blue (350ex/461em) channels. α-SMA
expression was assessed by quantifying fluorescence intensity and the percentage α-
SMA positive cells. More than 50 cells per dish were analyzed.
Gel contraction. Fibroblast contractile activity was assessed by collagen contrac-
tion assays in which 112,500 MEFs were seeded into a 2 mg/ml collagen type I
(Corning, 354249) gel matrix and cast into a 48-well plate. Once collagen poly-
merized, the gel was gently released from edges of the well and media was added to
the well. Images were taken using a Nikon SMZ1500 stereomicroscope at 0 and 24
after the gel was released from well edges. ImageJ software (NIH) was used to
calculate the surface area, which is presented as percent gel contraction relative to
initial size of the gel.
Cell proliferation. MEFs were seeded at the same density in 96-well plates and
quantified using the CyQUANT NF Cell Proliferation Assay Kit (ThermoFisher)
according to the manufacturer’s protocol.
qPCR mRNA analysis. RNA was isolated using the RNeasy Mini Kit (Qiagen,
74104) according to the manufacturer’s protocol. RNA (2 μg) was reverse tran-
scribed into cDNA using the High Capacity cDNA Reverse Transcription Kit
(ThermoFischer, 4368814) according to the manufacturer’s protocol. Thermocycler
conditions were as follows: 25 °C for 10 min, 37 °C for 2 h, 85 °C for 5 min.
Quantification of cDNA was done using Luminaris HiGreen qPCR Master Mix
(ThermoFischer, K0991) following the manufacturer’s protocol. Cycling conditions
were as follows: 95 °C for 10 min followed by 40 cycles of amplification (95 °C
denaturation for 15 seconds, 60 °C annealing/extension for 1 min). We evaluated
samples for mRNA expression of Collagen type I alpha 1 chain (Col1a1), Collagen
type I alpha 2 chain (Col1a2), Collagen type III alpha 1 chain (Col3a1), α-SMA
(Acta2), periostin (Postn), lysyl oxidase (Lox), fibronectin (Fn1), and platelet
derived growth factor receptor alpha (Pdgfra). Rps13 (Ribosomal Protein S13) was
used as a housekeeping gene. All samples were analyzed in duplicate and averaged.
Fold change in mRNA expression was measured using the Comparative CT
Method (2^-ΔΔCT). Primers used are listed below in Table 1.
NFAT translocation assay. MEFs were plated on coated 35 mm dishes and
infected with Ad-NFATc1-GFP for 24 h at which time live-cell images were taken
followed by treatment with 10 ng ml−1 TGFβ or 10 µM AngII for 24 h. For live-cell
imaging, cells were placed in a 37 °C heated chamber on a Carl Zeiss Axio Observer
Z1 fluorescent microscope. Prior to imaging, MEFs were incubated with Hoechst
33342 to demarcate cell nuclei. Images were acquired in the green channel (490ex/
525em) and blue channel (350ex/460em). NFAT localization was quantified as the
nuclear/cytoplasmic ratio of GFP fluorescence. More than 50 cells per dish were
analyzed.
Evaluation of mCa2+ uptake and efflux. Before permeabilization, MEFs were
washed in extracellular-like Ca2+-free buffer (120 mM NaCl, 5 mM KCl, 1 mM
KH2PO4, 0.2 mM MgCl2, 0.1 mM EGTA, 20 mM HEPEs-NaOH, pH 7.4). MEFs
(1.5 million) were then transferred to intracellular-like medium (ICM) (120 mM
KCl, 10 mM NaCl, 1 mM KH2PO4, 20 mM HEPES-Tris, protease inhibitors (Sigma
EGTA-Free Cocktail), 5 mM succinate, 2 µM thapsigargin, 40 µg ml−1 digitonin,
10 μM CGP-37157 (NCLX inhibitor), pH 7.2). ICM was cleared with Chelex 100 to
remove trace Ca2+ (Sigma). MEFs were gently stirred and 1 µM Fura-2 (Ther-
moFisher, F1200) was added to monitor extra-mitochondrial Ca2+. At 20 seconds,
JC-1 (Enzo Life Sciences) was added to monitor Δψ. Fluorescence signals were
monitored in a temperature controlled (37 °C) multi-wavelength-excitation/dual-
wavelength-emission spectrofluorometer (Delta RAM, Photon Technology Int.)
using 490-nm excitation (ex)/535-nm emission (em) for the JC-1 monomer,
570-nm ex/595-nm em for the J-aggregate of JC-1, and 340-nm and 380-nm ex/
510-nm em for Fura-2. At 350 seconds a Ca2+ bolus was added and clearance of
extra-mitochondrial Ca2+ was representative of mCa2+ uptake. At completion of
the experiment 10 µM of the protonophore FCCP was added to uncouple the Δψ
and release matrix free-Ca2+.
To quantify actual Ca2+ content, a standard curve of Ca2+ binding Fura-2 was
generated from serial diluted Ca2+ standards (0.01–120 µM) in ICM. The Kd was
calculated from the standard curve using GraphPad Prism 6.0 software. Fura-2
fluorescence ratio was converted to to [Ca2+] by the following equation: [Ca2+]=
Kd × (R− Rmin)/(Rmax− R) × Sf2/Sb2. (Rmin (ratio in 0–Ca2+)= 1.341; Rmax (ratio
at saturation)= 27.915; Sf2 (380/510 reading in 0-Ca2+) = 15822.14; Sb2 (380/510
reading with Ca2+ saturation)= 1794.32). The percentage of initial mCa2+ uptake
(200 s after Ca2+ addition) was plotted against the bath Ca2+ concentration for
each of the different Ca2+ boluses to generate a dose response curve.
ECAR and OCR measurements. A Seahorse Bioscience XF96 extracellular flux
analyzer was employed to measure extracellular acidification rates (ECAR) and
oxygen consumption rates (OCR). ECAR was measured using the Glycolytic Stress
mtCU gating, mCa
2+
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differentiation
TGFβ/AngII
MICU1
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Fig. 7 Enhanced mtCU gating is essential for myofibroblast differentiation.
Signaling model for myofibroblast differentiation whereby fibrotic stimuli
acutely upregulates MICU1 to limit mCa2+ uptake. Increased MICU1-
dependent mtCU gating leads to a cascade of metabolic changes necessary
for myofibroblast differentiation. Decreased [mCa2+] downregulates the
activity of Ca2+-dependent dehydrogenases (PDH, αKGDH). This elicits an
increase in glycolysis, which supports energetic demands during the
differentiation process and the activation of ancillary biosynthetic pathways
to support conversion into a myofibroblast. In addition, there are distinct
changes in the levels of TCA cycle intermediates, including increased αKG
bioavailability, which drives JmjC-KDM-dependent histone demethylation
for chromatin remodeling and activation of the myofibroblast gene program
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Test Kit (Seahorse Biosciences) and OCR was measured using the Mito Stress Test
Kit following the manufacturer’s protocol. To evaluate ECAR, 20,000 MEFs/well
were plated in XF media pH 7.4 without supplementation. Non-glycolytic acid-
ification was measured, then 10 mM glucose was injected to measure basal gly-
colysis, followed by 3 µM oligomycin to inhibit mitochondrial ATP production and
reveal maximal glycolytic capacity, and finally 50 mM 2-deoxy-glucose was injected
to completely inhibit all glycolysis. To evaluate OCR, 20,000 MEFs/well were plated
in XF media pH 7.4 supplemented with 10 mM glucose and 1 mM sodium pyr-
uvate. Basal OCR was measured, then 3 µM oligomycin was injected to inhibit
ATP-linked respiration, followed by 2 µM FCCP to measure maximal respiration,
and finally 1.5 µM rotenone/antimycin A was injected to completely inhibit all
mitochondrial respiration. After each experiment, protein concentration was
measured and wells were normalized using the Wave software.
Metabolomic profiling. Cells in a 10 cm dish were washed with 5% (w/w) man-
nitol (10 ml for the first wash, 2 ml for the second wash) and extracted in 800 μl
methanol plus 550 μl internal standard solution (Human Metabolome Technolo-
gies, HMT). Extracted solution was spun down at 2300 × g at 4 °C for 5 min. The
supernatant was transferred into centrifugal filter units (HMT) and centrifuged at
9100 × g at 4 °C for ~3.5 h until no liquid remained in the filter cup. Filtrate was
frozen at −80 °C and shipped to HMT for analysis by CE-TOFMS and CE-QqQMS
(Boston, MA). Filtrate was centrifugally concentrated and resuspended in 50 μl of
ultrapure water immediately before the measurement.
Cationic metabolites were analyzed using an Agilent CE-TOFMS system
(Agilent Technologies) Machine No. 3 and a fused silica capillary (i.d. 50 μm×
80 cm) with Cation Buffer Solution (HMT) as the electrolyte. The sample was
injected at a pressure of 50 mbar for 10 s. The applied voltage was set at 27 kV.
Electrospray ionization-mass spectrometry (ESI-MS) was conducted in the positive
ion mode, and the capillary voltage was set at 4000 V. The spectrometer was
scanned from m/z 50 to 1,000.
Anionic metabolites were analyzed using an Agilent Capillary Electrophoresis
System equipped with an Agilent 6460 TripleQuad LC/MS Machine No. QqQ3 and
a fused silica capillary (i.d. 50 μm× 80 cm) with Anion Buffer Solution (HMT) as
the electrolyte. The sample was injected at a pressure of 50 mbar for 25 s. The
applied voltage was set at 30 kV. ESI-MS was conducted in the positive and
negative ion mode, and the capillary voltage was set at 4000 V for positive and
3500 V for negative mode.
Peaks detected in CE-TOFMs analysis were extracted using automatic
integration software (MasterHands ver.2.17.1.11 developed at Keio University) and
those in CE-QqQMS analysis were extracted using automatic integration software
(MassHunter Quantitative Analysis B.06.00 Agilent Technologies, Santa Clara, CA,
USA) in order to obtain peak information including m/z, migration time, and peak
area. The peak area was then converted to relative peak area by the following
equation: Relative peak area=Metabolite Peak Area/(Internal Standard Peak
Area × Normalization Factor). The peaks were annotated based on the migration
times in CE and m/z values determined by TOFMS. Putative metabolites were then
assigned from HMT metabolite database on the basis of m/z and migration time.
All metabolite concentrations were calculated by normalizing the peak area of each
metabolite with respect to the area of the internal standard and by using standard
curves, which were obtained by three-point calibrations. A heat map was generated
using ClustVis68. Unit variance was applied to rows. Rows were clustered using
Manhattan distance and average linkage.
NAD(P) and NAD(P)H assays. NAD(P) and NAD(P)H ratios were measured
using the bioluminescent NAD(P)/NAD(P)H-Glo Assay (Promega), performed
according to the manufacturer’s protocol. Briefly, cells were seeded and treated in a
96-well plate. Cells were lysed and split into separate wells to measure NAD(P) and
NAD(P)H by selectively destroying the oxidized forms by heating in basic solution
and the reduced forms in acidic solution. Utilizing the NAD cycling enzyme and
reductase enzyme, the generated luciferin is used by the recombinant luciferase to
produce light. The determine the redox state of the cell, the NAD(P):NAD(P)H
ratio is reported.
DNA methylation. To extract genomic DNA, cells were collected and washed with
PBS followed by 2 h incubation at 60 °C in DNA isolation buffer (0.5% SDS,
100 mM NaCl, 50 mM Tris pH 8, 3 mM EDTA, 0.1 mg/ml proteinase K). DNA was
extracted using chloroform followed by ethanol precipitation and dissolved in
double-distilled water. DNA methylation was quantified using the MethylFlashTM
Methylated DNA Quantification Kit (Colorimetric), according to the manu-
facturer’s protocol (Epigentek Inc.). One hundred nanograms of input DNA were
used per reaction. Absorbance at 450-nm was measured using a Tecan Infinite F50
microplate reader.
ChIP-qPCR. ChIP-qPCR was performed using the ChIP-IT High Sensitivity Kit
(Active Motif, 53040) according to the manufacturer’s protocol. Cells were fixed,
lysed and sonicated for 30 m (30 s on, 30 s off) leading to chromatin fragments
between 200 and 1200 base pairs. DNA-bound protein was immunoprecipitated
using 2 μg anti-H3K27me2 (Active Motif, clone MABI 0324) or IgG (Santa Cruz,
2025). Following immuneprecipitation, cross-links were reversed, protein was
removed, and DNA was purified. qPCR was performed with equal amounts of
H3K27me2-immunoprecipitated sample, IgG-immunoprecipitated sample, and
input sample. Values were normalized to input measurements and fold enrichment
was calculated. qPCR primers were designed to target gene loci regions flanking or
nearby myofibroblast transcription factor predicted binding sites according to
Genomatrix-MatInspector Software analysis. The following ChIP-qPCR primers
were used: periostin forward primer 5′-CCACAGCCCAGAGCTATATAAAC-3′,
periostin reverse primer 5′-CAGCAGCAGCAGAGCATATAA-3′, platelet-derived
growth receptor alpha forward primer 5′-AGCAACTACACGGCACTTT-3′,
platelet-derived growth receptor alpha reverse primer 5′-CTGGGCCTCGCTAGA
AATATG-3′.
RNA-seq/ATAC-seq. RNA-seq and ATAC-seq were performed in cardiac
fibroblasts (CFs) treated with or without TGFβ for 24 h; 3 biological replicates. For
RNA-seq, total RNA was isolated from CFs using a standard RNA isolation kit
(Qiagen). The TrueSeq stranded mRNA library kit was used to enrich polyA
mRNAs via poly-T based RNA purification beads which were then amplified using
Hiseq rapid SR cluster kit and multiplexed and run using the HiSeq rapid SBS kit.
Reading depth was ~40M reads per sample and single-end 75 bp fragments were
generated for bioinformatic analysis using DESeq2 and assessed for quality control.
For ATAC-seq, gDNA was isolated from the same treated samples and incubated
with Tn5 transposomes which fragments and adds adapters simultaneously, in
open chromatin regions. Deep sequencing of these purified regions provides 50 bp
fragments and downstream base-pair resolution of nucleosome-free regions in the
genome. ATAC-seq data was then processed (trimmed, filtered, and quality con-
trolled) using the Illumina BaseSpace sequencing HUB and enriched regions were
identified using MACS2 analysis. Only those enriched regions found across all 3
biological samples were included in the analysis. All kits were obtained from
Illumina and all sequencing was performed on the Illumina HiSeq2500 sequencer.
Both sequencing data sets were aligned to the mouse genome (mm10). For data
visualization, BIGWIG files were generated for RNA-seq and ATAC-seq viewing in
the Integrative Genomics Viewer (Version 2.5).
Echocardiography. Transthoracic echocardiography of the left ventricle was per-
formed and analyzed on a Vevo 2100 imaging system (VisualSonics). Mice were
anesthetized with 2% isoflurane in 100% oxygen during acquisition. M-mode
images were collected in short-axis and analysis was performed using VisualSonics
software.
Myocardial infarction. Ligation of the left coronary artery (LCA) was performed
as described previously in Gao et al.69. Briefly, mice were anesthetized with 2%
isoflurane in 100% oxygen and the heart exposed via a left thoracotomy at the fifth
intercostal space. The LCA was permanently ligated to induce a large myocardial
infarction and the heart was returned to the chest cavity.
Chronic angiotensin II infusion. Mice were anesthetized with 2% isoflurane in
100% oxygen and mini-osmotic pumps (Alzet Model 1004) were inserted sub-
cutaneously to deliver 1.1 mg/kg/d Angiontesin II (Sigma, A9525) for 4 weeks.
Tissue gravimetrics. Mice were sacrificed followed by isolation and weighing of
the heart and lungs, as well as measurement of tibia length. Heart gravimetrics were
assessed by heart weight/tibia length ratios. Lungs were weighed at the time of
isolation (wet lung weight) and after dehydration at 37 °C for 1 week (dry lung
weight). Lung edema was quantified by subtracting wet–dry lung weight.
Histology. For histological analysis, hearts were collected at the indicated time
points and fixed in 10% buffered formalin. Next, hearts were dehydrated and
embedded in paraffin followed by collection of serial 7 μm sections. To evaluate
Table 1 qPCR Primers
Gene Forward primer 5′–3′ Reverse primer 5′–3′
Rps13 gcaccttgagaggaacagaa gagcacccgcttagtcttatag
Col1a1 ttcagggaatgcctggtgaa acctttgggaccagcatca
Col1a2 gaaaagggtccctctggagaa aataccgggagcaccaagaa
Col3a1 tgctggaaagaatggggagac ggtccagaatctcccttgtcac
Acta2 gtgaagaggaagacagcacag gcccattccaaccattactcc
Postn ccattggaggcaaacaactcc ttgcttcctctcaccatgca
Lox acgtcctgtgactatgggtac tctgccgcataggtgtcata
Fn1 cgtcattgccctgaagaaca aagggtaaccagttggggaa
Pdgfra caaagggaggacgttcaagac tgcgtccatctccagattca
Micu1 aagaacactccctgccattt gccagggtcatctgcattat
Mcu gatgacgtgacggtggttta gtcagagataggcttgagtgtg
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fibrosis, sections were stained with Masson’s trichrome (Sigma). Sections were
examined using a Nikon Eclipse Ni microscope and images were acquired with a
high-resolution digital camera (Nikon DS-Ri1). The percentage of fibrosis was
quantified using ImageJ software (NIH). Blue pixels were expressed as a percentage
of the entire image surface area.
To quantify myofibroblasts, antigen retrieval was performed and sections were
subsequently stained with anti-α-SMA antibody (1:1000, Sigma-Aldrich, A2547)
and anti-CD31 (1:30, R&D Systems, AF3628). Sections were incubated with
antibodies in a humidified chamber overnight at 4 °C followed by 1 h at room
temperature. Sections were washed three times for 5 min each in PBS and
incubated in secondary antibodies for 1 h at 37 °C in a humidified chamber.
Secondary antibodies used were: Alexa Fluor 488 (1:250, Invitrogen, A21202) and
Alexa Fluor 555 (1:100, Invitrogen, A21432). After washing three times for 5 min
each, sections were stained with DAPI (Invitrogen R37606). After DAPI staining,
sections were washed three times for 5 min and then incubated with Sudan black B
(Abcam, ab146284) for 40 min at room temperature followed by 6 washes for 10
min each. Finally sections were mounted on slides using Vectashield. Images were
taken using a Carl Zeiss Axio Observer Z1 fluorescent microscope. Images were
acquired in the green channel (490ex/525em), orange channel (555ex/580em), and
blue channel (350ex/460em). Eight images per heart were obtained for quantitative
analysis. Myofibroblast percentages were derived by counting the number of single
positive α-SMA cells (α-SMA+/ CD31−) and dividing by the total number of
nuclei.
Statistics and scientific rigor. All results are presented as mean +/− SEM. All
experiments were replicated at least 3 times if biological replicates were not
appropriate. Statistical powering was initially performed using the nQuery Advisor
3.0 software (Statistical Solutions) along with historical data to estimate sample
size. For all experiments, the calculations use α= 0.05 and β= 0.2 (power= 0.80).
Statistical analysis was performed using Prism 6.0 (GraphPad Software). Where
appropriate, column analyses were performed using an unpaired, 2-tailed t-test (for
2 groups) or one-way ANOVA (for groups of 3 or more). For grouped analyses
either multiple unpaired t-tests or where appropriate 2-way ANOVA with a Sidak
post-hoc analysis was performed. P values less than 0.05 (95% confidence interval)
were considered significant. For all in vivo studies, researchers were blinded from
mouse genotypes and a numerical ear tagging system enabled unbiased data col-
lection. Upon completion of the study, mouse ID numbers were cross-referenced
with genotype to permit analysis. Mice were excluded from the MI study if they
lacked a scar or infarct, as evaluated by histological staining at 4 weeks post-MI.
Data availability
The data that support the findings of this study are available from the corresponding
author upon reasonable request. All ATAC-sequencing and RNA-sequencing data has
been submitted to the GEO repository with accession # GSE135531.
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